Novo Nordisk A/S (NYSE:NVO) Shares Bought by Syon Capital LLC

Syon Capital LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 19.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 27,809 shares of the company’s stock after acquiring an additional 4,612 shares during the quarter. Syon Capital LLC’s holdings in Novo Nordisk A/S were worth $2,877,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in NVO. Meritage Portfolio Management grew its stake in Novo Nordisk A/S by 6.9% during the 4th quarter. Meritage Portfolio Management now owns 249,059 shares of the company’s stock worth $25,765,000 after buying an additional 16,159 shares during the last quarter. Lyell Wealth Management LP boosted its stake in Novo Nordisk A/S by 7.8% during the 4th quarter. Lyell Wealth Management LP now owns 2,754 shares of the company’s stock worth $285,000 after purchasing an additional 200 shares during the period. Atria Wealth Solutions Inc. increased its stake in Novo Nordisk A/S by 28.7% in the fourth quarter. Atria Wealth Solutions Inc. now owns 37,049 shares of the company’s stock valued at $3,833,000 after purchasing an additional 8,266 shares during the period. Wynn Capital LLC purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $749,000. Finally, Harvest Fund Management Co. Ltd grew its holdings in shares of Novo Nordisk A/S by 124.5% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 5,626 shares of the company’s stock worth $582,000 after buying an additional 3,120 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on NVO. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective for the company. UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Trading Up 0.8 %

Shares of NYSE NVO traded up $1.06 during trading on Friday, hitting $126.85. 3,209,438 shares of the company traded hands, compared to its average volume of 4,797,257. The company has a 50-day moving average price of $126.80 and a 200-day moving average price of $111.74. The firm has a market capitalization of $569.24 billion, a P/E ratio of 47.05, a P/E/G ratio of 2.11 and a beta of 0.41. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. On average, equities analysts predict that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a dividend of $0.664 per share. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.